Prognostic and predictive factors of breast carcinoma: Beyond hormonal receptors and HER2

European Journal of Cancer, Supplement

Volumn 6, Issue 14, 2008, Pages 1-3

  Nappi, Oscar ^a   Carrillo, Giovanna ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Breast cancer predictive markers; Breast cancer prognostic markers

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN;

ARTICLE; BREAST CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

EID: 55649101181     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2008.06.011     Document Type: Article

References (22)

1. Hanna W., Kahn H.J., and Trudeau M. Evaluation of HER2/neu (erB-2) status in breast cancer: from bench to bedside. Mod Pathol 12 (1999) 827-834
2. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER"-positive breast cancer: a randomized controlled trial. Lancet 369 (2007) 29-36
3. Osborne C.K. Steroid hormone receptors in breast cancer management Breast. Cancer Res Treat 51 (1998) 227-2386
4. Playne S.J.L., Bowen R.L., and Wells C.A. Predictive markers in breast cancer - the present. Histopathology 52 (2008) 82-90
5. Ellis I.O., Schnitt S.J., Sastre-Garau, et al. Invasive breast cancer. In: Tavassoli F., and Devilee P. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the breast and female genital organs (2003), IARC, Lyon 13-59
6. Goldhirsch A., Wood W.C., Gelber R.D., et al. Panel Members. Progress and promise: highlights of the international expert consensus on the primary of early breast cancer. Ann Oncol 18 (2007) 1133-1144
7. Arnould L., Dennoux Y., MacGrogan G., et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in determination of HER2 status in breast cancer. Br J Cancer 88 10 (2003) 1587-1591
8. Pauletti G., Dandekar S., Ramos L., et al. Assessment of methods for tissue-based detection of the HER2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18 21 (2000) 3651-3664
9. Harvey J.M., Clark G.M., Osborne C.K., et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 5 (1999) 1474-1481
10. Owens M.A., Horten B.C., and Da Silva M.M. Her2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5 (2004) 63-69
11. Perou C.M., Sorlie T., and Eisen M.B. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
12. Reis-Filho J.S., and Tutt A.N.J. Triple negative tumours: a critical review. Histopathology 52 (2008) 108-118
13. Diaz L.K., Cryns V.L., Symmans W.F., et al. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14 (2007) 419-430
14. Ranieri G., Patruno R., Ruggieri E., et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13 16 (2006) 1845-1857
15. Pritchard K.I., Messersmith H., Trudeau M., et al. Her2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26 5 (2008) 736-744
16. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumour inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 2 (2004) 117-127
17. Natha R., Yu D., Hung M.C., et al. Mechanism of disease: understaining resistance to HER2-targeted therapy inhuman breast cancer. Nat Clin Pract Oncol 3 5 (2006) 269-280
18. Piccart-Gebhart M, The evolution of treatment strategies. Aiming at the target. St.Gallen 2007 Breast; 2007:16 (suppl).
19. Liu B., Ordanez-Ercan D., Fan Z., et al. Downregulation of erb B3 abrogates erbb2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 120 (2007) 1874-1882
20. Holbro T., Beerli R.R., Maurer F., et al. The erbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100 15 (2003) 8933-8938
21. Sundvall M., Iljin K., Kipinen S., et al. Role of Erbb4 in breast cancer. J Mammary Gland Biol Neoplasia 13 2 (2008) 259-268
22. Singer C.F., Kostler W.J., and Huelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta (2008) [Mar 4 Epub ahead of print]